The epigenetic impact of suberohydroxamic acid and 5-Aza-2 '-deoxycytidine on DNMT3B expression in myeloma cell lines differing in IL-6 expression
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F22%3A10157748" target="_blank" >RIV/00098892:_____/22:10157748 - isvavai.cz</a>
Alternative codes found
RIV/61989592:15110/22:73614993 RIV/00216208:11110/22:10447687 RIV/61988987:17110/22:A2302JLI
Result on the web
<a href="https://www.spandidos-publications.com/10.3892/mmr.2022.12837" target="_blank" >https://www.spandidos-publications.com/10.3892/mmr.2022.12837</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3892/mmr.2022.12837" target="_blank" >10.3892/mmr.2022.12837</a>
Alternative languages
Result language
angličtina
Original language name
The epigenetic impact of suberohydroxamic acid and 5-Aza-2 '-deoxycytidine on DNMT3B expression in myeloma cell lines differing in IL-6 expression
Original language description
Gene inactivation of the cyclin-dependent kinase inhibitors p16INK4a, p15INK4b and p21WAF is frequently mediated by promoter gene methylation, whereas histone deacetylases (HDACs) control gene expression through their ability to deacetylate proteins. The effect of suberohydroxamic acid (SBHA) and 5-Aza-2'-deoxycytidine (Decitabine) (DAC) treatments on the transcription of CDKN2A, CDKN2B and CDKN1A genes, and their effects on molecular biological behavior were examined in two myeloma cell lines, RPMI8226 and U266, which differ in p53-functionality and IL-6 expression. In both tested myeloma cell lines, a non-methylated state of the CDKN2B gene promoter region was detected with normal gene expression, and the same level of p15(INK4b) protein was detected by immunocytochemical staining. Furthermore, in myeloma cells treated with SBHA and DAC alone, the expression of both p15INK4b and p21WAF was significantly upregulated in RPMI8226 cells (p53-functional, without IL-6 expression), whereas in the U266 cell line (p53 deleted, expressing IL-6) only p21WAF expression was significantly increased. Moreover, the analysis revealed that treatment with DAC induced DNMT3B enhancement in U266 cells. In conclusion, in myeloma cells with IL-6 expression, significantly increased DNMT3B expression indicated the tumorigenic consequences of 5-Aza-2'deoxycytidine treatment, which requires careful use in diseases involving epigenetic dysregulation, such as multiple myeloma (MM).
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Molecular Medicine Reports
ISSN
1791-2997
e-ISSN
1791-3004
Volume of the periodical
26
Issue of the periodical within the volume
4
Country of publishing house
GR - GREECE
Number of pages
14
Pages from-to
321
UT code for WoS article
000854740500001
EID of the result in the Scopus database
2-s2.0-85136952107